GlobeNewsWire
16 Aug 2026, 19:53 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Capricor Therapeutics faces allegations that it changed the statistical analysis plan for its Deramiocel clinical data without prior FDA agreement. — Lack of FDA alignment on primary endpoints significantly increases the risk of a BLA rejection, which is a binary catastrophic event for biotech valuations.
-0.80The lawsuit claims there is a substantial risk to the regulatory approval of Deramiocel for the treatment of Duchenne muscular dystrophy. — Directly challenges the viability of the company's core product pipeline and future revenue streams.
-0.60A securities class action lawsuit has been filed against Capricor Therapeutics alleging materially false or misleading statements regarding its business prospects. — Legal challenges and potential settlements create financial liabilities and signal poor corporate governance to institutional investors.
-0.40Which stocks this story touches
Continue reading
6 related stories
Search tags
The company is facing a securities class action lawsuit alleging materially false and misleading statements regarding clinical data and FDA approval risks.
The company is mentioned in the context of a reminder for purchasers to join a securities class action lawsuit.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
4h ago
